18 November – Targeted Treatments for Lung Cancer

Tuesday 18 November 2014, Christie Hospital, Manchester

Half-day course (1-6pm):  Targeted Treatments for Lung Cancer

Level: Advanced

Description:
This course provides a detailed description of the molecular pathology and classification of non-small cell lung cancer and small cell lung cancer, along with information on targeted treatments in use and in development for these diseases.
It explains the scientific rationale behind targeted treatments such as EGFR inhibitors (eg. erlotinib, gefitinib, afatinib), ALK inhibitors (eg. crizotinib), angiogenesis inhibitors (eg. bevacizumab) and immunotherapy (eg. ipilimumab & nivolumab).

Audience: Ideal for doctors, research nurses and other oncology staff caring for patients with lung cancer.

To book, contact: education.events@christie.nhs.uk

Programme:

Cancer: a disease of many layers
  • DNA damage: causes, types and consequences
  • Epigenetics – the chicken or the egg?
  • Cancer cells and their microenvironment – cellular diversity and cell-cell communication pathways
  • Cancer stem cells and the EMT
  • Genetic instability and intra-tumoural heterogeneity: the new enemies
Introducing non-small cell lung cancer
  • Mechanisms of development
  • The molecular landscape of adenocarcinoma and squamous cell carcinoma
Targeted treatments for non-small cell lung cancer
  • EGF-R targeted treatments (gefitinib, erlotinib, afatinib, dacomitinib & cetuximab)
  • ALK inhibitors (crizotinib, LDK378, alectinib)
  • VEGF-R & multi-kinase inhibitors
  • Novel targets and treatments eg. inhibitors of ROS1, RET, MET, BRAF, HER2, FGFR2
  • Immunotherapy (PD-1 and PDL-1 monoclonal antibodies)
Molecular pathology and targeted treatments for small cell lung cancer
  • The cellular & molecular landscape of small cell lung cancer
  • Targeted treatment approaches tried in small cell lung cancer
  • PARP, HSP90 and hedgehog pathway inhibitors

Amgen Ltd. have given funding towards the cost of this event but have had no input into the agenda.